March 1, 2022 08:00 am ETEstimated Read Time: 5 Minutes
The first legal psilocybin therapy program to take shape in America is slowly progressing in Oregon. The 17-person Psilocybin Advisory Board appointed by Gov. Kate Brown conducts regularly scheduled monthly meetings with a goal of shaping the nation’s first Psilocybin therapy program.
Oregon’s Psilocybin Therapy Program: Advisory Board Hard at Work
Oregon voters approved Measure 109 in November 2020 which has given birth to this program. After Measure 109 was passed, the Psilocybin Advisory Board— in collaboration with the Oregon Health Authority—began a two-year process of creating the regulatory and licensing framework for the psilocybin therapy program.
The campaign manager of the ‘Yes on 109’ campaign that helped see the measure passed, Sam Chapman, told media sources, “There’s a huge breadth of expertise on this board from harm reduction experts to folks that have experience working with different populations that stand to benefit from having access to psilocybin therapy. And so, we’re really excited to see such a diverse psilocybin advisory board with such a unique offering of experiences to bring to the table to create the best program possible.”
The Psilocybin Advisory Board has another year left to establish the licensing and regulatory framework for the state’s psilocybin therapy program. If everything goes according to plan, psilocybin therapy could be available publicly in Oregon as soon as 2023.
The Psilocybin Advisory Board noted that their goal is a complicated one due to the current federal listing of psilocybin as a Schedule I drug. In addition to navigating federal illegality, Oregon’s Psilocybin Advisory Board is tasked with laying the framework for maximizing safety training, as well as ensuring program remains equitable, affordable, and accessible for anyone who needs it.
What Is Psilocybin?
Psilocybin is a psychedelic compound that occurs naturally in over 200 different species of fungi. Different varieties of psilocybin have different potencies. Some of the most potent psilocybin varieties are P. semilanceata, P. azurescens, and P. cyanescens. More commonly, psilocybin is found in what many call magic mushrooms. There are many different varieties of magic mushrooms such as Golden Teachers, Apes, Magnolias, Liberty caps, and many others that are popular today.
Psilocybin mushrooms are classified as Schedule I drug—the same schedule as cannabis. Schedule I drugs are defined as substances with no accepted medical use and a high potential for abuse. Yet results from a 2020 John Hopkins study suggest that psilocybin may in fact have significant medical value.
Apply For Your Medical Marijuana Card Today
Veriheal has satisfied hundreds of thousands of patients nationwide
Get approved or your money back
Appointments available on-demand
Customer support available 24/7
Further research is needed, however it seems unwise to discount these findings and dismiss the evidence that points to the tremendous untapped potential in psychedelic medicine. A psychedelic therapy program like Oregon’s could help provide relief to millions suffering from conditions that currently don’t have effective treatments.
It may seem like a new concept to some, but there is a long history of psychedelic medicine in the United States and in the world. Like cannabis, there was a time before psychedelics were broadly criminalized and were used primarily for their medicinal properties.
A Brief History of Psychedelic Research
Although indigenous cultures have harnessed the power of psychedelic medicine for centuries, psilocybin was first isolated in a clinical setting by a Swiss chemist named Albert Hoffman and his coworkers. Mr. Hoffman is a legend in the field of psychedelics. He is also credited with the discovery of Lysergic acid diethylamide (LSD), mescaline, and many other psychedelic compounds. Hoffman first discovered LSD while trying to synthesize a different compound, and by accident a trace of LSD was absorbed through his fingers.
Intrigued by the experience, Hoffman began taking LSD along with other psychedelics while studying their effects. Albert Hoffman was said to have spent the last 25 years of his life microdosing LSD. Mr. Hoffman lived to be 102 years old, passing away in April of 2008. Despite the federal government halting research in the 1950’s, Hoffman’s research into the field of psychedelics laid the groundwork for countless others to participate in this field.
His research paved the way for Rick Doblin— founder of the Multidisciplinary Association for Psychedelic Studies (MAPS)—who advocated for psychedelic medicine and research in the 1980s. As a result of Doblin’s activism the first FDA-approved double-blind study of MDMA and its therapeutic potential was conducted in 1996. Oregon’s psychedelic therapy program wouldn’t exist without the research and activism of people like Hoffman and Doblin.
Oregon’s Psilocybin Therapy Program Paves the Way
Oregon is the first state in the nation to approve progressive laws supporting psilocybin. Other places have followed in their footsteps such as the city of Denver in Colorado, and our nation’s capital Washington DC. Other cities and states are looking to pass legislation to decriminalize psilocybin, such as Seattle, Maine, Michigan, and more.
Early research on psychedelics such as psilocybin, ketamine, and MDMA has produced promising results. There is already growing evidence that psychedelic therapy could provide the answer to treating illnesses such as treatment resistant depression, PTSD, addiction, anxiety and more.
Today, people are fighting for the right to choose natural psychedelic medications over prescription drugs that have not provided the relief promised. Could it be possible that psychedelic substances such as psilocybin could help treat mental health disorders like anxiety and depression where pharmaceuticals such as Wellbutrin, Amitriptyline, Thorazine, and Xanax have failed? Time—and continued research—will tell.
Ashley Priest is a patient, mother, entrepreneur, and activist that fights to end prohibition globally for a better future for all. Ashley has a passion for sharing education pertaining to the goddess plant known as cannabis. She believes that a single seed can tip the scales and that together through education we can end the stigma that is preventing cannabis from flowering to its full potential globally.
Suddenly, the world of magic mushrooms is almost as complicated as that of learning about cannabis. Shrooms or “magic” mushrooms have gained traction as a hallucinogenic therapeutic application for several different mental health circumstances such as depression and migraines—particularly when microdosing. It’s not just liberty caps anymore, folks. There are many different varieties and types…
Edibles are arguably one of the best means of recreational cannabis consumption—you get to eat a treat AND experience a long-lasting high. But it’s easy to end up dealing with some unwanted side effects due to the variability in the onset of these THC-packed goodies, which come in the form of brownies, cookies, gummies, chocolate,…
If you’re reading this, you are either a recreational cannabis veteran who has seen a handful of cannabis smokers passing out from puffing a joint and can’t seem to figure out why. Or, you are a newbie who wants to give recreational or medical cannabis a shot, and the burning question on your mind is,…
According to a new study published by the University of New Mexico (UNM) in the prestigious journal Frontiers in Pharmacology, researchers have unveiled a significant correlation between the sensation of “feeling high” and the relief of medical symptoms among cannabis patients. This landmark study probes uncharted territories, challenging pre-existing assumptions and opening new avenues for…
A survey illustrates psychedelics’ rapid rise, Herer Brands sues Daniel Herer, and Hulkamania comes to cannabis. Let’s dive into this week’s canna-news. Psychedelic Use Reaches Record High A new national survey conducted by Monitoring The Future found that psychedelic use is at an all-time high amongst U.S. adults. Conducted in 2022, the survey included approximately…
The statements made regarding cannabis products on this website have not been evaluated by the Food and Drug Administration (FDA). Cannabis is not an FDA-approved substance and is still illegal under federal law. The information provided on this website is intended for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not intended as medical advice and should not be considered as a substitute for advice from a healthcare professional. We strongly recommend that you consult with a physician or other qualified healthcare provider before using any cannabis products. The use of any information provided on this website is solely at your own risk.